Recruiting PHASE2/PHASE3 INTERVENTIONAL 3-arm NCT05504265

Perioperative Analgesia Modes in Minimally Invasive Esophagectomy

Comparison of Efficacy and Safety of Different Analgesic Modes in Minimally Invasive Esophagectomy for Esophageal Cancer

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Conditions Esophageal Cancer NSAIDs Opioid Patient-controlled Analgesia Perioperative Analgesia

Interventions Patient-controlled analgesia pump Postoperative flurbiprofen axetil Preemptive flurbiprofen axetil

Updated 4 times since 2022 Last updated: Mar 17, 2025 Started: Oct 10, 2022 Primary completion: Sep 30, 2025 Completion: Dec 20, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2/PHASE3 trial investigates Esophageal Cancer and NSAIDs and is currently actively recruiting participants. Cancer Institute and Hospital, Chinese Academy of Medical Sciences leads this study, which shows 4 recorded versions since 2022 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

4 versions recorded

Apr 2025 — Present [monthly]

Recruiting PHASE2/PHASE3

Status: Unknown → Recruiting
Sep 2024 — Apr 2025 [monthly]

Unknown PHASE2/PHASE3

Status: Not Yet Recruiting → Unknown
Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Sep 2022 — Jul 2024 [monthly]

Not Yet Recruiting PHASE2_PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Data source: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China